[go: up one dir, main page]

FI20030393L - Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi - Google Patents

Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi Download PDF

Info

Publication number
FI20030393L
FI20030393L FI20030393A FI20030393A FI20030393L FI 20030393 L FI20030393 L FI 20030393L FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A FI20030393 A FI 20030393A FI 20030393 L FI20030393 L FI 20030393L
Authority
FI
Finland
Prior art keywords
progression
predict
treat
compounds
methods
Prior art date
Application number
FI20030393A
Other languages
English (en)
Swedish (sv)
Other versions
FI20030393A7 (fi
FI20030393A0 (fi
Inventor
Pirkko Vihko
Veli Isomaa
Original Assignee
Molekyyliendokrinologian Tutki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molekyyliendokrinologian Tutki filed Critical Molekyyliendokrinologian Tutki
Priority to FI20030393A priority Critical patent/FI20030393L/fi
Publication of FI20030393A0 publication Critical patent/FI20030393A0/fi
Priority to EP04720024A priority patent/EP1603571A2/en
Priority to PCT/FI2004/000145 priority patent/WO2004080271A2/en
Publication of FI20030393A7 publication Critical patent/FI20030393A7/fi
Publication of FI20030393L publication Critical patent/FI20030393L/fi
Priority to US11/225,095 priority patent/US20060057628A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI20030393A 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi FI20030393L (fi)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393L (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
EP04720024A EP1603571A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
PCT/FI2004/000145 WO2004080271A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
US11/225,095 US20060057628A1 (en) 2003-03-14 2005-09-14 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393L (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Publications (3)

Publication Number Publication Date
FI20030393A0 FI20030393A0 (fi) 2003-03-14
FI20030393A7 FI20030393A7 (fi) 2004-09-15
FI20030393L true FI20030393L (fi) 2004-09-15

Family

ID=8565817

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030393A FI20030393L (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Country Status (4)

Country Link
US (1) US20060057628A1 (fi)
EP (1) EP1603571A2 (fi)
FI (1) FI20030393L (fi)
WO (1) WO2004080271A2 (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US8088758B2 (en) 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
RU2409581C2 (ru) * 2004-12-13 2011-01-20 Зольвай Фармасьютиклз Гмбх НОВЫЕ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ТИОФЕНПИРИМИДИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ
BRPI0419229A (pt) * 2004-12-13 2007-12-18 Solvay Pharm Gmbh derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
CN101884706B (zh) * 2010-07-01 2014-05-28 广州市花城制药厂 一种祛痰止咳颗粒的检测方法

Also Published As

Publication number Publication date
FI20030393A7 (fi) 2004-09-15
EP1603571A2 (en) 2005-12-14
WO2004080271A3 (en) 2004-11-04
FI20030393A0 (fi) 2003-03-14
WO2004080271A2 (en) 2004-09-23
US20060057628A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
EP1667680A4 (en) COMBINATION PROCEDURE FOR THE TREATMENT OF CANCER
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
EP1575580A4 (en) METHOD FOR TREATING CARCINOMA
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP1636359A4 (en) PROCESS FOR PAIN TREATMENT
EP1830876A4 (en) TREATMENT OF SKIN METALS
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
EP1677794A4 (en) METHODS OF TREATING DISORDERS
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1572093A4 (en) IMPROVED TREATMENT OF CANCER WITH GLUTAMINE
DE602004010856D1 (de) Bohrlochbehandlungsflüssigkeiten
DK1678085T3 (da) Fluidbehandlingsindretning
DK1885380T3 (da) Natriummetaarsenit til anvendelse til behandling af metastatiske neoplastiske sygdomme
FI20030393L (fi) Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
FI20041250L (fi) Massanhiutaloittaja
EP1694364A4 (en) BREAST CANCER TREATMENT AND PREVENTION SYSTEM
IL164214A0 (en) Use of interleukin-24 to treat ovarian cancer
EP1401377A4 (en) METHOD FOR TREATING CANCER
DE602004026773D1 (de) Verfahrensherstellung von ethern
MA28901B1 (fr) Methode de traitement de cancers
EP1789064A4 (en) ENHANCED ANTICANCER TREATMENT
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
NO20063114L (no) Enoxaparin for behandling av cancer
DE502004007941D1 (de) Hydrodynamischer Retarder oder hydrodynamische Kupplung

Legal Events

Date Code Title Description
FD Application lapsed